Marianne Mancini - Viking Therapeutics Chief Officer
| VKTX Stock | USD 32.75 0.94 2.79% |
Insider
Marianne Mancini is Chief Officer of Viking Therapeutics
| Age | 60 |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1268) % which means that it has lost $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.155) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to drop to -0.27 in 2025. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 443.4 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ryan Brown | Sarepta Therapeutics | 46 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| Rebecca MD | Madrigal Pharmaceuticals | 73 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 67 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Joseph Tucker | Enveric Biosciences | 56 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Kevin PharmD | Axsome Therapeutics | 46 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Ellen Welch | PTC Therapeutics | N/A | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Jeff York | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Michael Morneau, Vice Administration | ||
| Marianne Mancini, Chief Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 111.44 M | ||||
| Shares Owned By Insiders | 2.71 % | ||||
| Shares Owned By Institutions | 74.58 % | ||||
| Number Of Shares Shorted | 20.2 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 4.00 X | ||||
| EBITDA | (100.83 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.